中性粒细胞比例与系统性红斑狼疮肾炎及活动情况相关性
摘要
系统性红斑狼疮(SLE)中狼疮性肾炎患者和活动性狼疮患者的预后普遍较差,寻找合适的指征预测两者的发生对改善预后有重要意义。本研究结果显示在系统性红斑狼疮患者中,外周血中性粒细胞的水平和比例均显著高于对照组,肾炎组均显著高于非肾炎患者,活动性患者均显著高于非活动性患者。外周血中性粒细胞数目和比例预测狼疮肾炎ROC曲线下面积分别被为0. 665和0. 833。外周血中性粒细胞数目和比例预测狼疮活动的ROC曲线下面积分别为0. 628,0. 860。本研究证实,中性粒细胞比例与系统性红斑狼疮病情密切相关,高比例患者对于肾炎和狼疮活动应予以重视。
引文
[1]李春梅,童凤琴,马怡,等. CD11b单核苷酸多态性与中国汉族系统性红斑狼疮的研究[J].标记免疫分析与临床,2016,23(12):1365-8.
[2]彭玲,杨渝伟,王开正.自身抗体谱数据挖掘及SLE预测模型的建立[J].标记免疫分析与临床,2017,24(9):1001-6.
[3]向守宝,鲁巧云,张彩云.环磷酰胺联合泼尼松在系统性红斑狼疮治疗中的疗效及安全性分析[J].标记免疫分析与临床,2016,23(4):400-2.
[4]袁媛,赵毅,刘毅.中性粒细胞凋亡在系统性红斑狼疮发病机制的研究进展[J].西部医学,2017,29(7):1018-22.
[5] MADHVI M,BLAIR PA,ISENBERG D A,et al. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus[J]. Immunity,2016,44(3):683-97.
[6] KHAMASHTA M,MERRILL JT,WERTH V P,et al. Sifalimumab,an anti-interferon-αmonoclonal antibody,in moderate to severe systemic lupus erythematosus:a randomised,double-blind,placebo-controlled study[J]. Ann Rheum Dis,2016,75(11):1909.
[7] PALANICHAMY A,BAUER JW,YALAVARTHI S,et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus[J]. J Immunol,2014,192(3):906.
[8] FURIE R,KHAMASHTA M,MERRILL JT,et al. Anifrolumab,an anti-interferon-αreceptor monoclonal antibody,in moderate-tosevere systemic lupus erythematosus[J]. Arthritis Rheumatol,2017,69(2):376-86.
[9]刘晓庆,段亚男,石磊,等.红细胞分布宽度和中性粒细胞/淋巴细胞比值在系统性红斑狼疮中的应用价值[J].中国现代医生,2016,54(33):22-4.
[10]常俊,谌蓉.中性粒细胞/淋巴细胞比值、淋巴细胞/中性粒细胞比值与系统性红斑狼疮活动及狼疮肾炎的关系[J].医学信息,2017,30(24).
[11]常俊,谌蓉.中性粒细胞比例评估系统性红斑狼疮病情的应用价值[J].江苏医药,2017,43(23):1707-10.
[2]彭玲,杨渝伟,王开正.自身抗体谱数据挖掘及SLE预测模型的建立[J].标记免疫分析与临床,2017,24(9):1001-6.
[3]向守宝,鲁巧云,张彩云.环磷酰胺联合泼尼松在系统性红斑狼疮治疗中的疗效及安全性分析[J].标记免疫分析与临床,2016,23(4):400-2.
[4]袁媛,赵毅,刘毅.中性粒细胞凋亡在系统性红斑狼疮发病机制的研究进展[J].西部医学,2017,29(7):1018-22.
[5] MADHVI M,BLAIR PA,ISENBERG D A,et al. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus[J]. Immunity,2016,44(3):683-97.
[6] KHAMASHTA M,MERRILL JT,WERTH V P,et al. Sifalimumab,an anti-interferon-αmonoclonal antibody,in moderate to severe systemic lupus erythematosus:a randomised,double-blind,placebo-controlled study[J]. Ann Rheum Dis,2016,75(11):1909.
[7] PALANICHAMY A,BAUER JW,YALAVARTHI S,et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus[J]. J Immunol,2014,192(3):906.
[8] FURIE R,KHAMASHTA M,MERRILL JT,et al. Anifrolumab,an anti-interferon-αreceptor monoclonal antibody,in moderate-tosevere systemic lupus erythematosus[J]. Arthritis Rheumatol,2017,69(2):376-86.
[9]刘晓庆,段亚男,石磊,等.红细胞分布宽度和中性粒细胞/淋巴细胞比值在系统性红斑狼疮中的应用价值[J].中国现代医生,2016,54(33):22-4.
[10]常俊,谌蓉.中性粒细胞/淋巴细胞比值、淋巴细胞/中性粒细胞比值与系统性红斑狼疮活动及狼疮肾炎的关系[J].医学信息,2017,30(24).
[11]常俊,谌蓉.中性粒细胞比例评估系统性红斑狼疮病情的应用价值[J].江苏医药,2017,43(23):1707-10.